Helius Medical Technologies (HSDT) Stock Price, News & Analysis

Company Overview

Helius Medical Technologies, Inc. (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics. Frameworks of care vary by region but typically involve coordinated therapy protocols that combine the wearable stimulator, physical exercises and clinician-led monitoring. Helius supports its clinical users with training, device management and remote patient engagement tools to optimize rehabilitation outcomes.

Beyond its core PoNS offering, Helius is advancing an at-home digital therapy program that integrates software-guided exercises and telehealth support. The company collaborates with research institutions and rehabilitation centers to broaden the evidence base for its technology and explore applications in conditions such as mild traumatic brain injury, multiple sclerosis and stroke recovery. Ongoing clinical studies aim to expand indications and refine therapy protocols.

Founded in 2015 and headquartered in Toronto, Ontario, Helius Medical Technologies is led by President and Chief Executive Officer Dan M. Toutant. Since its inception, the company has pursued regulatory clearances across key markets and built partnerships with rehabilitation specialists to bring neuromodulation therapies to patients worldwide.

Key Stats

• Today's Range: $21.72 to $25.50
• 50-Day Range: $5.55 to $23.17
• 52-Week Range: $5.37 to $1,200.00
• Volume: 1.15 million shs
• Average Volume: 1.18 million shs
• Market Capitalization: $25.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Helius Medical Technologies Stock Analysis - MarketRank™

Helius Medical Technologies scored higher than 27% of companies evaluated by MarketBeat, and ranked 836th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Helius Medical Technologies.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Helius Medical Technologies is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Helius Medical Technologies is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Helius Medical Technologies has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.73% of the float of Helius Medical Technologies has been sold short.

Short Interest Ratio / Days to Cover

Helius Medical Technologies has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Helius Medical Technologies has recently decreased by 51.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Helius Medical Technologies does not currently pay a dividend.

Dividend Growth

Helius Medical Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.73% of the float of Helius Medical Technologies has been sold short.

Short Interest Ratio / Days to Cover

Helius Medical Technologies has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Helius Medical Technologies has recently decreased by 51.27%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.24

News Sentiment

Helius Medical Technologies has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Helius Medical Technologies this week, compared to 1 article on an average week.

Search Interest

9 people have searched for HSDT on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.

MarketBeat Follows

1 people have added Helius Medical Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Helius Medical Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.90% of the stock of Helius Medical Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 18.63% of the stock of Helius Medical Technologies is held by institutions.

HSDT Stock Analysis - Frequently Asked Questions

How have HSDT shares performed this year?

Helius Medical Technologies' stock was trading at $502.7250 at the beginning of 2025. Since then, HSDT shares have decreased by 95.4% and is now trading at $23.17.

How were Helius Medical Technologies' earnings last quarter?

Helius Medical Technologies, Inc. (NASDAQ:HSDT) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($79.73) earnings per share for the quarter, topping analysts' consensus estimates of ($128.50) by $48.77. The company earned $0.04 million during the quarter, compared to analyst estimates of $0.11 million. Helius Medical Technologies had a negative trailing twelve-month return on equity of 699.93% and a negative net margin of 7,215.25%.

When did Helius Medical Technologies' stock split?

Helius Medical Technologies shares reverse split on Tuesday, July 1st 2025.The 1-50 reverse split was announced on Friday, June 27th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Who are Helius Medical Technologies' major shareholders?

Helius Medical Technologies' top institutional investors include Wealthspire Advisors LLC (3,000.00%).
View institutional ownership trends.

How do I buy shares of Helius Medical Technologies?

Shares of HSDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Helius Medical Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Helius Medical Technologies investors own include HubSpot (HUBS), Mazor Robotics (MZOR), Netflix (NFLX), Riot Platforms (RIOT), Tesla (TSLA), Acasti Pharma (ACST) and

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/19/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:HSDT
• CIK: 1610853
• Web: heliusmedical.com
• Phone: (877) 564-0008
• Fax: N/A
• Employees: 30
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($1,976.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.74 million
• Net Margins: -7,215.25%
• Pretax Margin: -7,215.25%
• Return on Equity: -699.93%
• Return on Assets: -415.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.32
• Quick Ratio: 3.69

Sales & Book Value

• Annual Sales: $520 thousand
• Price / Sales: 48.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $212.95 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 1,080,000
• Free Float: 884,000
• Market Cap: $25.02 million
• Optionable: Not Optionable
• Beta: 0.74